PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

(2015) Joan Montero et al.   CELL

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

(2014) P. D. Garcia et al.   CLINICAL CANCER RESEARCH

PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer

(2014) Austin N. Kirschner et al.   JNCI-Journal of the National Cancer Institute

AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia

(2013) E. K. Keeton et al.   BLOOD

Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control

(2013) Emanuele de Rinaldis et al.   BMC GENOMICS

A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells

(2013) Fabio Petrocca et al.   CANCER CELL

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Tackling the Diversity of Triple-Negative Breast Cancer

(2013) N. C. Turner et al.   CLINICAL CANCER RESEARCH

The PIM Family of Serine/Threonine Kinases in Cancer

(2013) Maja Narlik-Grassow et al.   MEDICINAL RESEARCH REVIEWS

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles

(2013) Patrycja Gazinska et al.   MODERN PATHOLOGY

MYC-y mice: From tumour initiation to therapeutic targeting of endogenous MYC

(2013) Jennifer P. Morton et al.   Molecular Oncology

Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase

(2013) K Miura et al.   ONCOGENE

Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets

(2013) J. M. Balko et al.   Cancer Discovery

Molecular characterisation of cell line models for triple-negative breast cancers

(2012) Anita Grigoriadis et al.   BMC GENOMICS

MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors

(2012) Wajana L. Labisso et al.   CELL CYCLE

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors

(2012) Marjo Malinen et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

(2012) Nicola Aceto et al.   NATURE MEDICINE

Phosphorylation Regulates c-Myc's Oncogenic Activity in the Mammary Gland

(2011) X. Wang et al.   CANCER RESEARCH

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Contagious Cancer

(2011) J. S. Welsh   ONCOLOGIST

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo

(2011) Kristen L. Meerbrey et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity

(2011) Markus Rasmussen et al.   GENOME BIOLOGY

Why target PIM1 for cancer diagnosis and treatment?

(2010) Nancy S Magnuson et al.   Future Oncology

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

(2010) N Turner et al.   ONCOGENE

Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma

(2010) J Wang et al.   ONCOGENE

Allele-specific copy number analysis of tumors

(2010) P. Van Loo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

(2009) F. Andre et al.   CLINICAL CANCER RESEARCH

Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer

(2009) C. Speers et al.   CLINICAL CANCER RESEARCH

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response

(2009) Sanjay Chandriani et al.   PLoS One

Utilization of Pathway Signatures to Reveal Distinct Types of B Lymphoma in the E -myc Model and Human Diffuse Large B-Cell Lymphoma

(2008) S. Mori et al.   CANCER RESEARCH

Pim Kinases Promote Cell Cycle Progression by Phosphorylating and Down-regulating p27Kip1 at the Transcriptional and Posttranscriptional Levels

(2008) D. Morishita et al.   CANCER RESEARCH

Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6‘split apart’ probes

(2008) J S Reis-Filho et al.   HISTOPATHOLOGY